Embecta Corp (EMBC) Fair Value & Analysis
Healthcare · US · Market cap $185M
Embecta Corp
EMBC · US
Fair value as of: Jul 15, 2026
From 22 valuation models · updated today
Fair value updated Jul 15, 2026 — revised from $21.95 to $3.25 (−85.2%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range $2.89 – $14.85 · fair‑value band $2.46 – $3.94 · the $3.10 price screens below the $3.25 fair value. As of Jul 15, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Embecta Corp (EMBC) currently trades at $3.10, while our model-based Fair Value estimate is $3.25 — implying the stock looks roughly 4.7% fairly valued today. We read business quality at 53/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Embecta Corp generated revenue of $1.0B at a net margin of 10.7%. Revenue declined 14.4% year over year. Net debt stands at $1.2B. The stock trades on a trailing P/E of 1.6. Fundamentals as of Jul 15, 2026
Our scenario range runs from $2.46 (bear case) to $3.94 (bull case); at $3.10, the current price sits within that range. The share trades about 79% below its 52-week high and 12% above its 52-week low. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside — at 5%, EMBC screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 15, 2026. TTM = trailing twelve months.
About the company
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Embecta Corp reported revenue of $1.1B in FY2025 versus $1.2B in FY2021, a compound −1.9%/yr. Reported net income was $95.4M in FY2025, compounding −30.7%/yr from FY2021.
Is EMBC fairly valued? → Check now
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $412.02 | $165.35 | -60% |
| EssilorLuxottica Société anonyme ESLOF | $192.00 | $126.51 | -34% |
| HOYA Corporation HOCPY | $178.46 | $103.27 | -42% |
| Medline Inc MDLN | $33.61 | $31.78 | -5% |
| Becton, Dickinson and Company BDX | $149.56 | $117.04 | -22% |
| Alcon Inc ALC | CHF 53.28 | CHF 46.31 | -13% |
| ResMed Inc RMD | $193.57 | $187.89 | -3% |
| West Pharmaceutical Services, Inc WST | $336.39 | $143.45 | -57% |
| Terumo Corporation TRUMF | $14.62 | $12.65 | -13% |
| Straumann Holding SAUHY | $12.68 | $5.49 | -57% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Embecta Corp (EMBC) undervalued?
What is the fair value of EMBC?
What is the quality score of EMBC?
What is the revenue of Embecta Corp (EMBC)?
What is the net profit margin of EMBC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Embecta Corp analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.